Abstract:Abstract Background and Aims Dialysis therapies including peritoneal dialysis (PD) are described to lead to premature vascular aging, atherosclerosis and associated cardiomyopathies, which are associated with high cardiovascular morbidity and mortality. Chronic inflammation, incomplete clearance of uremic toxins, and dyslipidaemia, are factors affecting the vasculature system. However, how these factors affect the endothelium, the fist cell layer in contact with these molecules, and the molecular mechanisms triggered by uremic toxins remain poorly understood. In vitro and in vivo studies have shown that cytoprotective additives (e.g. dipeptide alanyl-glutamine (AlaGln) or kinase inhibitor lithium chloride (LiCl)) to PD fluids reduce peritoneal damage in mesothelial and endothelial (EC) cells. Their potential systemic effects were not studied so far. Here, we demonstrate, in a newly developed model system, the changes induced by chronic exposure to serum of PD patients in the proteome and secretome of endothelial cells, and the effects of cytoprotective additives. Method For modelling systemic conditions of PD patients, primary EC were cultured for 5 passages in medium containing 10% serum collected from PD patients (n = 26) during regular PET tests, or from healthy donors (n = 12). Cytoprotective additives were added in parallel experiments. Cells were stably labelled (SILAC) to differentiate cell and donor serum proteins and the cellular proteome and secretome profiles were analysed by quantitative mass spectrometry. Prior to analysis of the secretome, equalizer beads, to enrich low abundant and deplete high abundant proteins, were used. ECIS (Electric Cell-substrate Impedance Sensing), was used to measure barrier function, growth rate, and permeability. Results Proteome analysis revealed perturbation of major cellular processes by serum of PD patients including inflammatory related processes such TLR regulation and complement activation, as well membrane related processes such as extracellular matrix interactions and junctions, and plasma lipoprotein remodelling. Addition of LiCl counteracted cell-adhesion related proteins. ECIS analysis showed that in uremic conditions the EC monolayer has a decreased barrier function compared to healthy conditions, and LiCl partially restores the tightness of the membrane. Secretome analysis showed differentially regulated proteins related to oxidative stress, senescence-associated secretory phenotype (SASP), and apoptosis. Interestingly, in the secretome, LiCl addition counter regulated INHBA and tissue factor pathway inhibitor 2, both proteins related to vascular calcification. Conclusion Surprisingly few studies have analysed uremic effects on EC using proteomics approaches, and no reports of chronic settings, modelling the patient situation, are available. Our data demonstrates that EC react to serum factors of PD patients with increased inflammation, permeability and a secretory profile. Interestingly, our model reflects many of the known effects on the vasculature, but unravels the molecular mechanism that may induce those processes. We have also identified potential mechanisms by which the addition of cytoprotective additives may counteract some of the uremic effects systemically. Secretomics data identified several proteins secreted by EC that are regulated in uremia with potential for cellular crosstalk with other cells of the vasculature, showing the potential to identify therapeutic targets to reduce the cardiovascular risk of PD patients and current limitations of the therapy.

Effect Of Chronic Renal Failure Medium On The Ubiquitin-Proteasome Pathway Of Arterial Muscle Cells

p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells

Effect of Autophagy on Cardiac Myocytes Injury in Uremic Cardiomyopathy Mice

Uremic Serum Induces Osteogenic Transition and Calcification of Human Umbilical Artery Smooth Muscle Cells

[Effect of serum from patients with chronic renal insufficiency and indoxyl sulfate on lipid accumulation in macrophages in vitro].

Uremic Toxin Receptor AhR Facilitates Renal Senescence and Fibrosis Via Suppressing Mitochondrial Biogenesis.

Lack of Rab27a Attenuates Foam Cell Formation and Macrophage Inflammation in Uremic Apolipoprotein E Knockout Mice

[The Role of Foxo1 and Ubiquitin-Proteasome System Markers in Muscle Atrophy Caused by Chronic Kidney Disease].

Urea-induced ROS cause endothelial dysfunction in chronic renal failure

In Vitro Injury Effects of Sera of Patients with Uremia on Vascular Endothelial Cells

Roles of AhR/CYP1s signaling pathway mediated ROS production in uremic cardiomyopathy

#5930 ENDOTHELIAL CELL PROTEOME AND SECRETOME ALTERATION UNDER CHRONIC UREMIC EXPOSURE

Uremic Toxins Are Conditional Danger‐ or Homeostasis‐ Associated Molecular Patterns, Which Are Highly Selective Increase Rather Than Purely Passive Accumulation, in Chronic Kidney Disease and Coronary Arteria Disease

Roles of AhR/CYP1s Signal Pathway Mediated ROS Production in Uremic Cardiomyopathy

UCP1 alleviates renal interstitial fibrosis progression through oxidative stress pathway mediated by SIRT3 protein stability

A study on the change of autophagy in skeletal muscle of patients with chronic kidney disease

Atherosclerosis and Vascular Calcification in Chronic Renal Failure

Effect of calcium phosphate crystals induced by uremic serum on calcification of human aortic smooth muscle cells

Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions

Effects of Uremia Serum on Monolayer Permeability and F-actin in Rat Pulmonary Microvascular Endothelial Cells

Translational Medicine in Uremic Vascular Calcification: Scavenging ROS Attenuates p-Cresyl Sulfate-Activated Caspase-1, NLRP3 Inflammasome and Eicosanoid Inflammation in Human Arterial Smooth Muscle Cells